Cabaletta Bio, Inc. (CABA)

12.53 -0.07 (-0.56%) As of 10:36AM EDT. Market open.

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
https://www.cabalettabio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 101

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Steven A. Nichtberger M.D.	Co-Founder, Chairman, CEO & President	970.6k	N/A	1961
Dr. Gwendolyn K. Binder Ph.D.	President of Science & Technology	692.99k	N/A	1975
Dr. David J. Chang FACR, M.D., M.P.H.	Chief Medical Officer	676.74k	N/A	1963
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Mr. Anup Marda M.B.A.	Chief Financial Officer	548.2k	N/A	1978
Dr. Samik Basu M.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Michael Gerard J.D.	General Counsel & Secretary	N/A	N/A	1980
Ms. Heather Harte-Hall M.Sc.	Chief Compliance Officer	N/A	N/A	N/A
Ms. Martha O'Connor	Chief Human Resources Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Cabaletta Bio, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.